MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) — Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, today provided a corporate update and announced its strategic priorities and anticipated milestones.
“The past year was one of substantial progress with the advancement of our lead program, ELU001, into the clinic for the treatment of solid tumors overexpressing folate receptor alpha (FRα). Importantly, recent release of pivotal data for an antibody drug conjugate (ADC) also directed at FRα further validated the target and increased our confidence in ELU001,” said Geno Germano, President and CEO of Elucida Oncology.
“Today, I am excited to announce that we have entered into a research collaboration with a major pharmaceutical company for the development of two novel CDCs, which further expands our pipeline of novel drug conjugates. Looking ahead, 2022 could represent another step-change in the evolution of the company, with interim Phase 1 data of ELU001 in the first half of the year and identification of a recommended Phase 2 dose (R2PD) in the second half. We believe our CDC’s greater avidity for the antigen and tumor retention combined with delivery of a larger amount of drug payload could produce efficacy even in patients with lower expression of FRα while rapid renal clearance could translate into a more favorable safety profile, addressing key limitations of ADCs. In addition, we expect our research collaboration to yield preclinical data that could inform the selection of a lead candidate by year-end,” added Mr. Germano.
Strategic Priorities and Milestones
ELU001: Lead CDC clinical candidate for patients with advanced, recurrent, or refractory solid tumors expressing folate-receptor alpha enters third dose level in ongoing Phase 1/2 trial.
Pipeline Expansion: Select lead for partnered program and advance multiple wholly owned candidates.
Manufacturing: Scaled manufacturing for ELU001 in anticipation of demand from Phase 2 trials.
Business Development: Elucida continues to focus on executing on numerous business development opportunities available through its CDC platform.
About Elucida Oncology:
Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear® properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers. For more information on Elucida Oncology, Inc., please visit www.elucidaoncology.com.
Investor and BD Contact: | Media Contact: |
M. Ian Somaiya | media@elucidaoncology.com |
Chief Financial and Business Officer | |
Elucida Oncology, Inc. | |
isomaiya@elucidaoncology.com |
NEWTOWN, Pa., Dec. 22, 2024 /PRNewswire/ -- The law firm of Edelson Lechtzin LLP is…
Miami, Florida--(Newsfile Corp. - December 21, 2024) - Amid the vibrant backdrop of Art Basel…
Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…
MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…